Eurofins Viracor Launches Rapid CAR T-Cell Monitoring Assay for Obe-cel Therapy
核心洞察
Eurofins Viracor (搜索) has launched the ExPeCT™ anti-CD19 (搜索) (obe-cel) CAR T-cell assay, a specialized diagnostic test designed to monitor the performance of obecabtagene autoleucel CAR T-cell therapy.
The non-invasive blood test delivers results in approximately 24 hours after specimen receipt, enabling real-time monitoring of CAR T-cell expansion and persistence.
The assay was developed exclusively for testing second-generation obe-cel CAR T-cells, potentially helping clinicians make timely therapy decisions for immunocompromised patients.
Eurofins Viracor (搜索) announced the launch of the ExPeCT™ anti-CD19 (搜索) (obe-cel) CAR T-cell assay on March 26, 2026, marking a significant advancement in monitoring capabilities for next-generation immunotherapy. The cutting-edge diagnostic solution is designed to help clinicians monitor CAR T-cell therapy performance with validated precision and rapid turnaround times.
Real-Time Monitoring Capabilities
The ExPeCT™ brand of CAR T-cell assays enables clinicians to monitor CAR T-cell expansion and persistence in real time through a non-invasive blood test. The assay delivers results in approximately 24 hours after specimen receipt, potentially helping clinicians make timely therapy decisions for patients receiving CAR T-cell treatments.
Specialized Focus on Obe-cel Therapy
The assay was developed exclusively to test the expansion and persistence of obecabtagene autoleucel (obe-cel) CAR T-cells, which represents a second-generation CAR T-cell therapy. This specialized focus allows for precise monitoring of this specific therapeutic approach, providing clinicians with targeted diagnostic capabilities for patients receiving obe-cel treatment.
Clinical Impact and Applications
The rapid turnaround time of approximately 24 hours represents a significant improvement in monitoring capabilities for CAR T-cell therapies. This quick response time could enable healthcare providers to make more informed and timely decisions regarding patient care and treatment adjustments during the critical period following CAR T-cell infusion.
Company Background and Expertise
Eurofins Viracor (搜索) brings over 40 years of diagnostic expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients to this new assay development. The company operates as a subsidiary of Eurofins Scientific (搜索), a global leader in bio-analytical testing with over 65,000 staff across more than 950 laboratories in over 1,000 companies across 59 countries.
The launch of this specialized assay reflects the growing need for precise monitoring tools in the rapidly evolving field of CAR T-cell immunotherapy, particularly for patients receiving advanced second-generation treatments like obe-cel.